This announcement is a separate document:
君实生物自愿披露关于特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的III期临床研究达到主要研究终点的公告
Junshi Bio has voluntarily disclosed an announcement regarding the phase III clinical study of the combination of Teriprizumab and Bevacizumab as first-line treatment for advanced hepatocellular carcinoma reaching the primary endpoint.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated